The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m

Applied Radiation and Isotopes

Volumn 67, Issue 9, 2009, Pages 1616-1621

  Asikoglu, Makbule ^a   Gamze Durak, Funda ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

99mTc Zoledronic acid; Bisphosphonates; Gamma scintigraphy; Radiolabeling; Technetium 99m; Zoledronic acid

Indexed keywords

99MTC-ZOLEDRONIC ACID; BISPHOSPHONATES; GAMMA SCINTIGRAPHY; RADIOLABELING; TECHNETIUM-99M; ZOLEDRONIC ACID;

ACIDS; CHLORINE COMPOUNDS; CHROMATOGRAPHIC ANALYSIS;

TECHNETIUM;

BISPHOSPHONIC ACID DERIVATIVE; MEDRONATE TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; STANNOUS CHLORIDE; TECHNETIUM 99M; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BONE SCINTISCANNING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG STABILITY; EPIPHYSIS; FEMUR; ISOTOPE LABELING; KIDNEY; LUMBAR VERTEBRA; NONHUMAN; PAPER CHROMATOGRAPHY; PRIORITY JOURNAL; ROOM TEMPERATURE;

ANIMALS; DIPHOSPHONATES; EPIPHYSES; FEMUR; IMIDAZOLES; KIDNEY; LUMBAR VERTEBRAE; MALE; ORGANOTECHNETIUM COMPOUNDS; RABBITS; RADIOPHARMACEUTICALS;

EID: 67349163564     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.04.009     Document Type: Article

References (21)

1. Bagi C.M. Targeting of therapeutic agents to bone to treat metastatic cancer. Adv. Drug Del. Rev. 57 7 (2005) 995-1010
2. Body J.J. Clinical research update: zoledronate. Cancer 80 8 (1997) 1699-1701
3. Cheer S.M., and Noble S. Zoledronic acid. Drugs 61 (2001) 799-805
4. Croucher P., Jagdev S., and Coleman R. The anti-tumor potential of zoledronic acid. The Breast 12 2 (2003) 30-36
5. 99mTc for bone imaging and biodistribution studies in rabbits. Chosen abstracts of 12th European Symposium on Radiopharmacy and Radiopharmaceuticals, Sopot. Nucl. Med. Rev. 7 2 (2004) 212
6. 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer. Nucl. Med. Biol. 33 6 (2006) 715-722
7. 99mTc diphosphonate uptake mechanism on bone. In: Fogelman I. (Ed). Bone Scanning in Clinical Practice (1987), Springer, New York 7-17
8. Green J.R. Bisphosphonates in cancer therapy. Cur. Opin. Oncol. 14 (2002) 609-615
9. Green J.R. Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J. Organometallic Chem. 690 10 (2005) 2439-2448
10. Grey A., Bolland M.J., Wattie D., Horne A., Gamble G., and Reid I.R. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J. Clin. Endocrinol. Metab. 94 (2009) 538-544
11. Kowalsky R.J., and Perry J. Radiopharmaceuticals in Nuclear Medicine Practice (1987), Appleton and Lange, Norwalk, Connecticut/Los Altos, California
12. Li E.C., and Davis L.E. Zoledronic acid: a new parenteral bisphosphonate. Clin. Ther. 25 11 (2003) 2669-2708
13. Major P., Lortholary A., Hon J., Abdi E., Mills G., Menssen H.D., Yunus F., Bell R., Body J., Quebe-Fehling E., and Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19 (2001) 558-567
14. Martin-Jimenez T., De-Lorimier L.P., Fan T.M., and Freise K.J. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs. J. Vet. Pharmacol. Ther. 30 5 (2007) 492-495
15. 99mTc-MDP uptake to regional osseous circulation in skeletally immature and mature dogs. Skel. Radiol. 8 2 (1982) 115-121
16. 99mTc-labeling of ior egf/r3 monoclonal antibody: equivalence studies. Biotecnologia Aplicada 17 1 (2000) 39-44
17. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Wonderling D., Normand C., and Broadley K. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol. Assess. 4 (2004) 1-16
18. Skerjanec A., Berenson J., Hsu C., Major P., Miller W.H., Ravera C., Schran H., Seaman J., and Waldmeier F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol. 43 2 (2003) 154-162
19. Subramanian G., McAfee J.G., Blair R.J., Kallfelz F.A., and Thomas F.D. Technetium-99m-methylene diphosphonate a superior agent for skeletal imaging: comparison with other technetium complexes. J. Nucl. Med. 16 8 (1975) 744-755
20. Weiss H.M., Pfaar U., Schweitzer A., Wiegand H., Skerjanec A., and Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab. Dispos. 36 10 (2008) 2043-2049
21. Warrell R.P. Metabolic emergencies. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles and Practice of Oncology. fifth ed. (1997), Lippincott Co, Philadelphia 2486-2493